Connettivina plus 2 mg + 40 mg - treatment of sores, ulcers, burns - 10 gauzes 10x10

Product Description

Composition:

Active ingredients: Hyaluronic acid sodium salt, Silver sulfadiazine. CONNETTIVINA PLUS 0.2% + 1% cream. 100 g of cream contains: Hyaluronic acid sodium salt 200 mg, Silver sulfadiazine 1.00 g. CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes. Each 10x10 cm gauze is soaked with 4 g of cream. CONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes. Each 10x20 cm gauze is soaked with 8 g of cream. CONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes. Each 20x30 cm gauze is soaked with 24 g of cream with the following percentage composition: Hyaluronic acid sodium salt 50 mg, Silver sulfadiazine. 1.00 g

Excipients

CONNETTIVINA PLUS 0.2% + 1% cream Polyethylene glycol 400 monostearate - oleic acid decyl ester - emulsifying wax - glycerol - sorbitol solution 70% - purified water CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes CONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes CONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes Polyethylene glycol 4000 - glycerol - purified water

Therapeutic indications

Prophylaxis and local treatment of sores, varicose ulcers and burns.

Contraindications

Hypersensitivity to the components of the product or other closely related substances from chemical point of view.

Dosage

CONNETTIVINA PLUS 0.2% + 1% cream: spread a uniform layer of cream 2-3 mm thick over the entire lesion site, once or twice a day. CONNETTIVINA PLUS 2 mg + 40 mg impregnated gauzes CONNETTIVINA PLUS 4 mg + 80 mg impregnated gauzes CONNETTIVINA PLUS 12 mg + 240 mg impregnated gauzes apply one or more medicated gauzes two or more times a day depending on the extent of the lesions. The application must continue without interruption until complete healing.

Warnings and precautions

CONNETTIVINA PLUS should be used with caution in subjects who have previously shown allergies to sulfonamides and in the presence of hepatic or renal insufficiency.

Interactions

Local proteolytic enzymes, applied simultaneously with CONNETTIVINA PLUS, can be inactivated by the presence of silver ions.

Undesirable effects

Following the application of CONNETTIVINA PLUS, local reactions of modest severity may rarely occur. No reports of systemic adverse reactions have ever been received, in fact the percutaneous absorption of CONNETTIVINAPLUS is negligible. However, since the systemic administration of sulfonamides can cause serious side effects, the risk of serious side effects is high. Although CONNETTIVINA PLUS may cause adverse reactions such as renal failure, toxic hepatitis, agranulocytosis, thrombocytopenia and leukopenia, it cannot be excluded that the treatment of large parts of the body with CONNETTIVINA PLUS may give rise to classic side effects of systemically administered sulphonamides.

Pregnancy and breastfeeding

Since there are no exhaustive experimental data on the possible side effects of the drug on the fetus, CONNETTIVINA PLUS should not be used during pregnancy and breastfeeding unless, in the doctor's opinion, its use is essential.

Format

10 gauzes